Viridian Metals Inc

Veligrotug met all primary and secondary endpoints in THRIVE-2 phase 3 trial for chronic TED, showing significant improvements in proptosis, diplopia, and CAS with a 56% PRR and 32% diplopia resolution rate. Well-tolerated with a 9.6% placebo-adjusted hearing impairment rate. BLA submission on track for 2025. VRDN-003 trials ongoing, with topline data expected in 2026. Viridian has a strong cash position of $753M as of September 2024.

Veligrotug met primary and secondary endpoints in phase 3 trial for chronic thyroid eye disease, showing improvements in proptosis, clinical activity scores, and diplopia. Viridian plans to submit a biologics license application in 2025.

A form includes dropdowns for selecting a state, zip code, and country, with options covering U.S. states, territories, and international countries.

Viridian Therapeutics will host a webcast on December 16, 2024, at 8:00 a.m. ET to present topline results from its THRIVE-2 Phase 3 trial, evaluating veligrotug's efficacy and safety in chronic thyroid eye disease (TED) patients. Investors can access the webcast via the company's website or by phone.

The FcRn inhibitor market report by ResearchAndMarkets.com provides insights into historical and competitive landscapes, market trends, emerging drugs, and forecasts from 2020 to 2034. Key players like Johnson & Johnson, UCB Biopharma, Pfizer, and Immunovant are developing FcRn inhibitors for autoimmune diseases. Prominent drugs include VYVGART, RYSTIGGO, and batoclimab, with positive trial results and FDA approvals. The market is expected to grow due to increasing diagnoses and emerging therapies.

The 'Graves' Disease - Pipeline Insight, 2024' report by ResearchAndMarkets.com provides a comprehensive overview of the current pipeline landscape for Graves' Disease treatments, including detailed descriptions of drugs like Batoclimab, VRDN-001, and Linsitinib, which are in various stages of clinical development. The report highlights key companies such as Viridian Therapeutics, Immunovant Sciences, and Sling Therapeutics, and covers therapeutic assessments, pipeline development activities, and emerging trends in drug development for Graves' Disease.

Umoja Biopharma appoints Scott Myers as Chairman of its Board of Directors, succeeding Dieter Weinand who will remain as an advisor. Myers, with extensive biotech experience, aims to transform CAR-T cell therapy delivery.

miRNA therapeutics face challenges like off-target effects and delivery issues, despite promising preclinical results. Unlike siRNA, no miRNA-based drug has reached phase 3 trials or been FDA-approved. miRNA's potential as a diagnostic tool is more immediate, with miRNA panels already in clinical use.